Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab

Eur J Dermatol. 2017 Oct 1;27(5):528-530. doi: 10.1684/ejd.2017.3071.
No abstract available

Publication types

  • Letter
  • Multicenter Study

MeSH terms

  • Age of Onset
  • Dermatologic Agents / pharmacokinetics
  • Dermatologic Agents / therapeutic use*
  • Female
  • HLA-C Antigens / genetics*
  • Humans
  • Male
  • Polymorphism, Genetic*
  • Psoriasis / drug therapy*
  • Psoriasis / genetics*
  • Psoriasis / metabolism
  • Retrospective Studies
  • Treatment Outcome
  • Ustekinumab / pharmacokinetics
  • Ustekinumab / therapeutic use*

Substances

  • Dermatologic Agents
  • HLA-C Antigens
  • Ustekinumab